new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Incyte Corporation
Incyte Corporation A Delaware Corporation
Incyte Corporationn A Delaware Corporation

Popular
Companies


Web
Adobe patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

  

Incyte Corporation patents


      
Recent patent applications related to Incyte Corporation. Incyte Corporation is listed as an Agent/Assignee. Note: Incyte Corporation may have other listings under different names/spellings. We're not affiliated with Incyte Corporation, we're just tracking patents.

ARCHIVE: New 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "I" | Incyte Corporation-related inventors




Search recent Press Releases: Incyte Corporation-related press releases
Count Application # Date Incyte Corporation patents (updated weekly) - BOOKMARK this page
12010002252201/28/10 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
22016013762605/19/16 Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
32016013765005/19/16 Imidazo[1,2-b][1,2,4]triazines as c-met inhibitors
42016013033205/12/16 Antibodies to human signal peptide-containing proteins
52016011516404/28/16 Bicyclic heterocycles as fgfr4 inhibitors
62016007572103/17/16 Tricyclic heterocycles as bet protein inhibitors
72016006725303/10/16 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
82016004665002/18/16 Tricyclic heterocycles as bet protein inhibitors
92016002268501/28/16 Heterocyclylamines as pi3k inhibitors
102016002410901/28/16 Tricyclic fused thiophene derivatives as jak inhibitors
112016002411701/28/16 Heterocyclylamines as pi3k inhibitors
122016001569501/21/16 Tricyclic fused thiophene derivatives as jak inhibitors
132016000971101/14/16 Triazolopyridines and triazolopyrazines as lsd1 inhibitors
142016000971201/14/16 Imidazopyridines and imidazopyrazines as lsd1 inhibitors
152016000971401/14/16 Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
162016000972001/14/16 Imidazopyrazines as lsd1 inhibitors
172016000972101/14/16 Triazolopyridines and triazolopyrazines as lsd1 inhibitors
182016000972601/14/16 Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
192016000079501/07/16 Treatment of b-cell malignancies by a combination jak and pi3k inhibitors
202015036109412/17/15 Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
212015034295212/03/15 Treatment of chronic neutrophilic leukemia (cnl) and atypical chronic myeloid leukemia (acml) by inhibitors of jak1
222015034449712/03/15 Processes of preparing a jak1 inhibitor and new forms thereto
232015032953411/19/15 Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
242015032956111/19/15 Amido compounds and their use as pharmaceuticals
252015031518511/05/15 Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-5-yl-amines as janus kinase inhibitors
262015030749310/29/15 1h-pyrrolo[2,3-c]pyridin-7(6h)-ones and pyrazolo[3,4-c]pyridin-7(6h)-ones as inhibitors of bet proteins
272015029170110/15/15 Methods for treating disorders associated with human signal peptide-containing molecules
282015028439010/08/15 N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
292015025079009/10/15 Topical formulation for a jak inhibitor
302015024604609/03/15 Jak1 inhibitors for the treatment of myelodysplastic syndromes
312015023849208/27/15 Heteroaryl substituted pyrrolo[2,3-b] pyridines and pyrrolo[2,3-b] pyrimidines as janus kinase inhibitors
322015022537508/13/15 Cyclopropylamines as lsd1 inhibitors
332015022537908/13/15 Cyclopropylamines as lsd1 inhibitors
342015022539408/13/15 Cyclopropylamines as lsd1 inhibitors
352015022540108/13/15 Cyclopropylamines as lsd1 inhibitors
362015022541108/13/15 Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
372015021817408/06/15 Processes for preparing jak inhibitors and related intermediate compounds
382015021069207/30/15 Spirocycles as inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1
392015019037807/09/15 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3- dioxygenase
402015018380507/02/15 Processes and intermediates for making a jak inhibitor
412015017560406/25/15 Tricyclic heterocycles as bet protein inhibitors
422015016490006/18/15 Metabolites of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
432015014834205/28/15 Bicyclic heterocycles as bet protein inhibitors
442015014834805/28/15 Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
452015014837205/28/15 Bicyclic heterocycles as bet protein inhibitors
462015014837505/28/15 Bicyclic heterocycles as bet protein inhibitors
472015013367405/14/15 Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor
482015008763203/26/15 Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidines derivatives as jak inhibitors
492015008766203/26/15 Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors
502015006544703/05/15 Survival benefit in patients with solid tumors with elevated c-reactive protein levels
512015006548403/05/15 Sustained release dosage forms for a jak1 inhibitor
522015005726502/26/15 Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
532015002505601/22/15 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases
542015001717301/15/15 Antibodies to human transmembrane proteins
552015001154001/08/15 Tricyclic heterocycles as bet protein inhibitors
562015000416501/01/15 Secreted proteins
572014037729212/25/14 Modulators of indoleamine 2,3-dioxygenase and methods of using the same
582014037840012/25/14 Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
592014037121612/18/14 Purinone derivatives as hm74a agonists
602014034303011/20/14 Bipyrazole derivatives as jak inhibitors
612014031596210/23/14 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3- dioxygenase
622014027503009/18/14 Tricyclic heterocycles as bet protein inhibitors
632014027503109/18/14 Piperidin-4-yl azetidine derivatives as jak1 inhibitors
642014027512709/18/14 Substituted heteroaryl fused derivatives as pi3k inhibitors
652014025694109/11/14 Processes and intermediates for making a jak inhibitor
662014024913209/04/14 Use of pyrazolopyrimidine derivatives for the treatment of pi3k-delta related disorders
672014024208608/28/14 Polynucleotides encoding signal peptide-containing molecules
682014024330808/28/14 Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
692014024336008/28/14 Heteroaryl substituted pyrrolo[2,3-b] pyridines and pyrrolo[2,3-b] pyrimidines as janus kinase inhibitors
702014022727508/14/14 Methods of treating and diagnosing pancreatitis
712014022727808/14/14 Antibodies to human signal peptide-containing proteins
722014022834608/14/14 Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-5-yl-amines as janus kinase inhibitors
732014022137908/07/14 N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
742014020021607/17/14 Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
752014020022707/17/14 Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
762014018753007/03/14 Aza spiro alkane derivatives as inhibitors of metalloproteases
772014017140506/19/14 Fused pyrazoles as fgfr inhibitors
782014017140906/19/14 Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
792014015528806/05/14 Methods for diagnosing cancer
802014015537706/05/14 3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors
812014015540406/05/14 Piperazinylpiperidine derivatives as chemokine receptor antagonists
822014013535005/15/14 Sustained-release dosage forms of ruxolitinib
832014012119805/01/14 Tricyclic fused thiophene derivatives as jak inhibitors
842014012122205/01/14 Pyrimidinones as pi3k inhibitors
852014006644803/06/14 Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
862014005690602/27/14 Secreted proteins
872014005791202/27/14 Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
882014004581402/13/14 Pyrazine derivatives as fgfr inhibitors
892014003134401/30/14 Azepine inhibitors of janus kinases
902014002366301/23/14 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
912014001837401/16/14 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
922014000516601/02/14 Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
932014000521001/02/14 Heteroaryl substituted pyrrolo[2,3-b] pyridines and pyrrolo[2,3-b] pyrimidines as janus kinase inhibitors
942013034515712/26/13 Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
952013034522412/26/13 Imidazo[1,2-b][1,2,4]triazines as c-met inhibitors
962013032451512/05/13 Imidazotriazines and imidazopyrimidines as kinase inhibitors
972013025319009/26/13 Processes for preparing jak inhibitors and related intermediate compounds
982013025319109/26/13 Processes for preparing jak inhibitors and related intermediate compounds
992013025319309/26/13 Processes for preparing jak inhibitors and related intermediate compounds
1002013024378109/19/13 Signal peptide-containing proteins
1012013024492709/19/13 Polynucleotides encoding signal peptide-containing molecules
1022013024499909/19/13 Substituted heterocyclic compounds
1032013022476908/29/13 Methods of using chemokine panec-1 antibodies
1042013022555608/29/13 Azetidine and cyclobutane derivatives as jak inhibitors
1052013019025007/25/13 Polynucleotides encoding human signal peptide-containing proteins
1062013017759007/11/13 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
1072013013768105/30/13 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
1082013012324605/16/13 Modulators of indoleamine 2,3-dioxygenase and methods of using the same
1092013011623005/09/13 3-aminopyrrolidine derivatives as modulators of chemokine receptors
1102013009614404/18/13 Isoindolinone and pyrrolopyridinone derivatives as akt inhibitors
1112013005894203/07/13 Human beta-adrenergic receptor kinase polypeptide and methods
1122013005983503/07/13 Heterocyclylamines as pi3k inhibitors
1132013006002603/07/13 Processes and intermediates for making a jak inhibitor
1142013004596302/21/13 Cyclohexyl azetidine derivatives as jak inhibitors
1152013001803401/17/13 Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
1162013001806801/17/13 Spirocycles as inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1
1172012032978212/27/12 Azepine inhibitors of janus kinases
1182012030146411/29/12 Janus kinase inhibitors for treatment of dry eye and other eye related diseases
1192012029591211/22/12 Piperazinylpiperidine derivatives as chemokine receptor antagonists
1202012027080910/25/12 Human transmembrane proteins
1212012012285805/17/12 Lactam compounds and their use as pharmaceuticals
1222012004096402/16/12 N-substituted piperidines and their use as pharmaceuticals
1232012003517202/09/12 Purinone derivatives as hm74a agonists
1242012001493701/19/12 Human beta-adrenergic receptor kinase polypeptide and methods
1252012001592801/19/12 Amido compounds and their use as pharmaceuticals
1262011025121510/13/11 Macrocyclic compounds and their use as kinase inhibitors
1272011021296709/01/11 Imidazo[1,2-b][1,2,4]triazines as c-met inhibitors
1282011020775408/25/11 Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors
1292011013678106/09/11 Imidazotriazines and imidazopyrimidines as kinase inhibitors
1302011008681004/14/11 Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d] pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
1312011008215904/07/11 Metabolites of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
1322011005321703/03/11 Polynucleotides encoding signal peptide-containing molecules
1332010027933311/04/10 Methods of treatment with antibodies to a chemokine expressed in inflamed adenoid
1342010025611410/07/10 Amido compounds and their use as pharmaceuticals
1352010024067109/23/10 Substituted heterocyclic compounds
1362010020303908/12/10 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
1372010019080407/29/10 Macrocyclic compounds and their use as kinase inhibitors
1382010017390107/08/10 Substituted heterocyclic compounds
1392010013740106/03/10 2-methylprop anamides and their use as pharmaceuticals
1402010011950305/13/10 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
1412010009961704/22/10 Secreted proteins
1422009031840512/24/09 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
1432009029194611/26/09 Lactam compounds and their use as pharmaceuticals
1442009028677411/19/09 Purinone derivatives as hm74a agonists
1452009028677811/19/09 Macrocyclic compounds and their use as kinase inhibitors
1462009027468011/05/09 Human phospholipases
1472009023390309/17/09 Azetidine and cyclobutane derivatives as jak inhibitors
1482009021576608/27/09 Tetracyclic inhibitors of janus kinases
1492009019788708/06/09 Piperazinylpiperidine derivatives as chemokine receptor antagonists
1502009018195907/16/09 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
1512009012464905/14/09 Aza spiro alkane derivatives as inhibitors of metalloproteases
1522009008844604/02/09 Purinone derivatives as hm74a agonists
1532009007626903/19/09 Purinone derivatives as hm74a agonists
1542012026367610/18/12 Compositions, methods and kits relating to her-2 cleavage
1552012005807903/08/12 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
1562012001498901/19/12 Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-5-yl-amines as janus kinase inhibitors
1572011031147912/22/11 Modulators of indoleamine 2,3-dioxygenase and methods of using the same
1582011022321009/15/11 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
1592011022415709/15/11 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
1602011017227907/14/11 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
1612011016518807/07/11 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
1622011008683504/14/11 Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-5-yl-amines as janus kinase inhibitors
1632009029880812/03/09 Inhibitors of 11-beta hydroxyl steroid dehydrogenase type i and methods of using the same
1642009019786908/06/09 Azepine inhibitors of janus kinases



ARCHIVE: New 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Incyte Corporation in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Incyte Corporation with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###